We are live on ! Find out more
IDYA icon

IDEAYA Biosciences

112 hedge funds and large institutions have $677M invested in IDEAYA Biosciences in 2022 Q3 according to their latest regulatory filings, with 28 funds opening new positions, 47 increasing their positions, 22 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

711,300% more call options, than puts

Call options by funds: $7.11M | Put options by funds: $1K

133% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 12

114% more repeat investments, than reductions

Existing positions increased: 47 | Existing positions reduced: 22

38% more capital invested

Capital invested by funds: $489M → $677M (+$188M)

17% more funds holding

Funds holding: 96112 (+16)

5.04% more ownership

Funds ownership: 91.7%96.74% (+5%)

25% less funds holding in top 10

Funds holding in top 10: 43 (-1)

Holders
112
Holders Change
+16
Holders Change %
+16.67%
% of All Funds
1.93%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.05%
New
28
Increased
47
Reduced
22
Closed
12
Calls
$7.11M
Puts
$1K
Net Calls
+$7.11M
Net Calls Change
+$245K
Name Holding Trade Value Shares
Change
Change in
Stake
N
26
Nuveen
North Carolina
$3.98M +$273K +21,010 +9%
CS
27
Candriam SCA
Luxembourg
$3.81M +$3.32M +255,317 New
NCM
28
Nantahala Capital Management
Connecticut
$3.78M +$3.29M +253,480 New
GCM
29
Ghisallo Capital Management
Massachusetts
$2.61M +$2.27M +175,000 New
CCM
30
CAAS Capital Management
New York
$2.52M +$2.2M +169,080 New
First Manhattan
31
First Manhattan
New York
$2.46M +$2.15M +165,200 New
TCM
32
Tekla Capital Management
Massachusetts
$1.99M +$1.73M +133,185 New
Bank of New York Mellon
33
Bank of New York Mellon
New York
$1.8M +$162K +12,480 +11%
Bank of America
34
Bank of America
North Carolina
$1.67M +$751K +57,856 +107%
Rafferty Asset Management
35
Rafferty Asset Management
New York
$1.67M +$883K +67,952 +154%
Goldman Sachs
36
Goldman Sachs
New York
$1.67M +$139K +10,730 +11%
IBT
37
International Biotechnology Trust
United Kingdom
$1.63M +$1.4M +107,499 +7,162%
Citigroup
38
Citigroup
New York
$1.57M -$1.27M -97,988 -48%
Ensign Peak Advisors
39
Ensign Peak Advisors
Utah
$1.5M +$70K +5,390 +6%
Charles Schwab
40
Charles Schwab
California
$1.37M +$11.5K +885 +1%
Swiss National Bank
41
Swiss National Bank
Switzerland
$1.35M +$349K +26,900 +42%
UOC
42
UBS O'Connor
Illinois
$1.2M +$1.04M +80,112 New
JAMONY
43
Jacob Asset Management of New York
California
$1.11M +$249K +19,135 +35%
Barclays
44
Barclays
United Kingdom
$1.05M +$886K +68,244 +2,887%
SCM
45
Sio Capital Management
New York
$1.04M +$909K +70,000 New
Ameriprise
46
Ameriprise
Minnesota
$933K -$24.8K -1,913 -3%
MIM
47
Monashee Investment Management
Massachusetts
$895K +$779K +60,000 New
RhumbLine Advisers
48
RhumbLine Advisers
Massachusetts
$801K +$47.7K +3,671 +7%
BNP Paribas Financial Markets
49
BNP Paribas Financial Markets
France
$796K +$581K +44,768 +522%
Morgan Stanley
50
Morgan Stanley
New York
$732K -$481K -37,023 -43%

IDYA Hedge Fund Activity: Q3 2022 in Review

112 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in IDEAYA Biosciences (IDYA) for Q3 2022, worth a combined $677M — up 38% from $489M a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new IDYA positions and 12 closed out — a net gain of 16 holders — while 47 added to existing stakes and 22 trimmed.

The largest buyer was Adage Capital Partners, adding an estimated $22.7M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $20.8M sold.

  • 112 institutional investors held IDEAYA Biosciences (IDYA) as of Q3 2022, up from 96 in Q2 2022.
  • Funds reported $677M of IDEAYA Biosciences stock for Q3 2022, up 38% quarter-over-quarter.
  • 28 funds opened new IDEAYA Biosciences positions in Q3 2022 and 12 closed out, a net change of +16 holders.
  • The largest IDEAYA Biosciences buyer in Q3 2022 was Adage Capital Partners, an estimated $22.7M added.
  • The largest IDEAYA Biosciences seller in Q3 2022 was Point72 Asset Management, an estimated $20.8M sold.

Based on aggregated 13F filings for Q3 2022.